$CYTR Company News CytRx's stock spike proves to be no

New Post Public Reply Private Reply Replies (0) Message Board

Dec 12, 2013 at 2:34 PM

$CYTR Company News

CytRx's stock spike proves to be no fluke with another 20% share gain 11:39 a.m. Today - Russ Britt
MasterCard, Visa among top S&P gainers; Avon in red 4:27 p.m. Dec. 11, 2013 - Sue Chang
Cancer drug test results send CytRx shares soaring by 75% 10:48 a.m. Dec. 11, 2013 - Russ Britt
CytRx jumps on results of aldoxorubicin trial 9:47 a.m. Dec. 11, 2013 - MarketWatch.com
Yum shares drop on outlook, soft China sales 5:10 p.m. Oct. 8, 2013 - Wallace Witkowski
Six companies unveil share, unit offerings 7:45 a.m. Dec. 7, 2012 - MarketWatch.com
Insider filings one way to track tricky micro-cap biotechs 11:14 a.m. Oct. 24, 2012 - blogs.marketwatch.com
CytRx prices offering at 20% discount 10:07 a.m. Oct. 18, 2012 - MarketWatch.com
CytRx down 20.6% in premarket 7:59 a.m. Oct. 18, 2012 - Steve Gelsi
CytRx rallies 27% on drug study update 11:49 a.m. July 25, 2012 - Val Brickates Kennedy
CytRx falls 12% in morning trading 10:02 a.m. June 4, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 3:40 p.m. April 28, 2011 - Kate Gibson
Dyax, Santarus, CytRx soar; Hemispherx craters 11:38 a.m. Dec. 2, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 5:00 p.m. June 30, 2009 - MarketWatch
Drug stocks retract; Vical, Geron, Novavax soar 1:29 p.m. June 30, 2009 - Val Brickates Kennedy
CytRx files FDA report on halted clinical trial 8:16 a.m. June 30, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:39 p.m. Jan. 22, 2008 - MarketWatch
Drug stocks tumble on U.S. economy jitters; CytRx slumps 1:33 p.m. Jan. 22, 2008 - Val Brickates Kennedy
CytRx halts trial of ALS treatment 7:50 a.m. Jan. 22, 2008 - Angela Moore
FDA puts hold on CytRx's Phase IIb arimoclomol trial 7:34 a.m. Jan. 22, 2008 - Michael Kitchen

CytRx Surges As Aldoxorubicin Dominates Doxorubicin In Phase 2B Tests 12:28 p.m. Today - Seeking Alpha
CytRx Surges As Aldoxorubicin Dominates Doxorubicin In Phase IIB Tests 12:28 p.m. Today - Seeking Alpha
Perilous Reversal Watch: CytRx Corporation (CYTR) 9:55 a.m. Today - TheStreet.com
CytRx Corporation Soars on Positive Phase 2b Sarcoma Data 1:38 p.m. Dec. 11, 2013 - Wall St. Cheat Sheet
Why CytRx (CYTR) Is Exploding on Wednesday 1:32 p.m. Dec. 11, 2013 - TheStreet.com
CytRx's Sarcoma Treatment Shows Positive Results 9:48 a.m. Dec. 11, 2013 - WSJ.com
Morning Market Movers 8:56 a.m. Dec. 11, 2013 - benzinga.com
CytRx reports positive top-line data from aldoxorubicin STS trial 8:23 a.m. Dec. 11, 2013 - Seeking Alpha
CytRx Corporation Offers Hope for Brain Cancer Patients 11:23 a.m. Dec. 5, 2013 - Wall St. Cheat Sheet
Top Insider Trades: CYTR TROX KTOS MDGN 9:50 a.m. Dec. 4, 2013 - TheStreet.com
CytRx rallies after conference presentation 8:19 a.m. Dec. 4, 2013 - Seeking Alpha
Aegis still positive on CytRx, sees big upside 9:50 a.m. Nov. 25, 2013 - Seeking Alpha
CytRx Initiates Phase 2 Aldoxorub Trial in Patients with Unresectable GBM Brain Cancer 7:40 a.m. Nov. 20, 2013 - benzinga.com
A Small Cap That is Cashing In on ObamaCare 3:44 p.m. Nov. 19, 2013 - benzinga.com
Aldoxorubicin Continues To Prove Itself As A Viable Cancer Treatment 10:40 a.m. Nov. 19, 2013 - Seeking Alpha
CytRx Surges Ahead With Positive Drug Data 7:41 a.m. Nov. 1, 2013 - Seeking Alpha
CytRx Announces Further Positive Clinical Data from Global Phase 2b Aldoxorubicin Study 5:03 a.m. Oct. 31, 2013 - benzinga.com
10-Q: CYTRX CORP 6:02 a.m. Oct. 29, 2013 - Edgar Online - (EDG = 10Q, 10K)
CytRx Says Wins FDA Acceptance for Protocol of Phase 2 Aldoxorubicin in Glioblastoma Trial 7:36 a.m. Oct. 23, 2013 - benzinga.com
CytRx Awaiting Soft Tissue Sarcoma Data In December 8:56 a.m. Oct. 17, 2013 - Seeking Alpha

Bullish Stocks Radar: CytRx Corporation, Echo Therapeutics Inc, Advanced Micro Devices, Inc, Baidu Inc 9:02 a.m. Dec. 11, 2013 - ACCESSWIRE
CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial 8:17 a.m. Dec. 11, 2013 - BusinessWire
CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas 5:30 p.m. Dec. 10, 2013 - BusinessWire
CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th, 2013 8:30 a.m. Dec. 4, 2013 - BusinessWire
CytRx to Present at the Sixth Annual LD MICRO "Main Event" Conference in Los Angeles on December 3, 2013 8:30 a.m. Nov. 26, 2013 - BusinessWire
CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin in Patients with Unresectable Glioblastoma Multiforme (Brain Cancer) 8:30 a.m. Nov. 20, 2013 - BusinessWire
MissionIR Releases Exclusive Audio Interview With CytRx Management 8:31 a.m. Nov. 7, 2013 - Marketwire
CytRx Reports Further Positive Interim Data from Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas 5:00 a.m. Oct. 31, 2013 - BusinessWire
CytRx Reports 2013 Third Quarter Financial Results 5:00 a.m. Oct. 29, 2013 - BusinessWire
Hot Topic: Breast Cancer Awareness Month 2013 7:08 a.m. Oct. 25, 2013 - BusinessWire
CytRx Announces Closing of Public Offering of Common Stock 11:45 a.m. Oct. 15, 2013 - BusinessWire
CytRx Announces Exercise of Underwriters' Over-Allotment Option 6:00 p.m. Oct. 11, 2013 - BusinessWire
Exclusive Video Interviews With CEOs Now on Equities.com: CGIX, CYTR, GWPH, HTBX, OPXA 7:01 a.m. Oct. 9, 2013 - GlobeNewswire
CytRx Announces Pricing of Public Offering of 10.0 Million Shares of Common Stock 8:15 p.m. Oct. 8, 2013 - BusinessWire
CytRx Announces Proposed Public Offering of Common Stock 3:20 p.m. Oct. 8, 2013 - BusinessWire
OtcbbJournal.com, Where Savvy Traders Get Their Small-Cap Stock Research 7:02 a.m. Sept. 30, 2013 - Marketwire
CytRx's New Aldoxorubicin Data Demonstrates Significant Advantages over Doxorubicin 5:00 a.m. Sept. 30, 2013 - BusinessWire
CytRx to Present at the Aegis Capital Corp. 2013 Healthcare Conference 7:30 a.m. Sept. 23, 2013 - BusinessWire
CytRx to Present at the Rodman & Renshaw Global Investment Conference 7:30 a.m. Sept. 3, 2013 - BusinessWire
CytRx Reports 2013 Second Quarter Financial Results 7:30 a.m. Aug. 6, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...